再鼎医药有限公司（股票代码：09688）于2026年6月22日发布公告，披露已根据2015、2017、2022及2024年股权激励计划向董事及其他参与人发行新股，导致公司已发行股本变动。
本次发行分为两部分：其一，向董事以外参与人发行1,031,840股普通股，约占原已发行股本（不含库藏股）总数的0.11%，每股发行价为0港元；其二，向公司董事发行2,668,160股普通股，约占原已发行股本（不含库藏股）总数的0.42%，每股发行价同样为0港元。发行完成后，公司已发行股本增至1,137,828,030股，库藏股数量仍为0股。
公司在公告中表示，相关股份发行已经获得董事会正式授权并遵守了所有适用的上市规则、法律及其他监管规定。该公告由公司秘书F. Ty Edmondson签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.